Description
Bionomics is dedicated to making better treatments for cancer, & central nervous system disorders such as anxiety, depression and Alzheimer's disease.
Tell your friends
RECENT FACEBOOK POSTS
facebook.com3 fast-growing biotech shares at the top of my watch list
Bionomics has been named as one of three fast-growing stocks to watch by a respected investment newsletter. Read the details here: http://bit.ly/2ffMyHr
bit.ly
Bionomics' CEO Dr Deborah Ratjhjen has brought investors up to date on the company's fortunes over the past year. You can read and see her AGM address here: http://bit.ly/2fx4FHd
www.bionomics.com.au
Did you miss the Bionomics Annual General Meeting? No problem. You can read the Chairman's address here: http://bit.ly/2fx4FHd
Bionomics
Bionomics
Trials look positive for new anxiety drug
National media coverage overnight of our BNC-210 clinical trial results. Watch here: https://yhoo.it/2fwGxqr
Media Center: Bionomics Limited (ASX:BNO): Presentation, ASX Spotlight Series, Hong Kong
Bionomics' CEO & MD Dr Deborah Rathjen has presented at the ASX Spotlight Series in Hong Kong. Watch it here: http://bit.ly/2f2JnRQ
Timeline Photos
Bionomics is excited to be part of the upcoming ASX Spotlight Series of investor presentations in Hong Kong and Singapore. The spotlight series offers ASX listed companies the opportunity to present to, and meet with, international investors. Bionomics’ presentations will take place tomorrow at 2:10pm in the Atrium room, Island Shangri-La, Hong Kong; and on Thursday at 10.00am in the Gallery Room, Grand Hyatt, Singapore. Can't make it? No problem. Presentations will also be on our website afterwards.
Timeline Photos
Investment research platform Seeking Alpha says the very positive Phase 2 clinical trial results from BNC210 as a treatment for anxiety and depression means the future looks bright for Bionomics: http://bit.ly/2dnNzva
Timeline Photos
President Barack Obama is talking about PTSD and its devastating effects during his Presidential Town Hall Address in Virginia tonight. Reinforces the importance of Bionomics' clinical trials into BNC210 as a treatment for PTSD and anxiety.
Timeline Photos
Here's a direct link to the Bionomics website, where you can read the remarkable coverage of the company by analysts from Bioshares. We're rated a Spec Buy, Class A: http://bit.ly/2dAXkFp
Timeline Photos
Bioshares devotes five pages of analyst coverage to Bionomics in its current issue and rates us a Speculative Buy Class A. It's a great read: http://bit.ly/2cUJw7E
Quiz
